Crizotinib, which inhibits ALK, MET, RON and ROS-1, was one of the first ALK inhibitors which proved effective in ALK mutated NSCLC with a positive effect on progression free survival (PFS) [27,28]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.